CHEK2 and diffuse large B-cell lymphoma: In summary, our study uncovered the association between HBV infection and resistance to MTX- or Ara-C-based chemotherapy mediated by the inhibition of CHK2 response signaling, which provides new insight into the role of HBV in the chemoresistance of DLBCL patients.